Medivir promotes Christine Lind to CEO

9 February 2017

Christine Lind has been appointed as the new chief executive of Swedish drugmaker Medivir (OMX: MVIR).

She succeeds Niklas Prager, who accepted the role as CEO in 2014 from a position as a director of the board when the company faced the need of a corporate transformation. Ms Lind will take up her new position on April 1, 2017, until which time she will continue in her existing role as executive vice president, strategic business development.

Niklas Prager will continue as CEO until 1 April and will also make himself available to Ms Lind until the Annual General Meeting on May 3, in order to ensure an optimal and smooth transition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK